Cytomegalovirus (CMV) disease is one of the leading reasons for mortality in immunocompromised patients. Opportunistic primary or recurrent CMV infection is involved in the acquired immunodeficiency syndrome (22, 23) and also causes interstitial pneumonia in bone marrow transplant recipients after iatrogenic immunosuppression (21, 25) . In the immunocompetent host, CMV infection is effectively controlled, and virus persists in a latent state. CD8 (T8)-positive cytolytic T lymphocytes (CTL) have been implicated in the recovery from CMV infection (25) . Viral gene expression in lymphocytes and monocytes of seropositive patients was found to be arrested after the expression of immediate-early (IE) genes (33) , the first set of herpesvirus genes transcribed under permissive conditions (8) , and CTL have been reported to recognize infected cells at an early time during the viral replication cycle (1) .
We have studied protective immunity to CMV in a murine model system with particular respect to the virus-specified antigens involved. The present state of knowledge can be briefly reviewed as follows.
(i) During acute, intraplantar infection of immunocompetent BALB/c mice, replication of murine CMV (MCMV) is restricted to glandular epithelial cells in the salivary glands, while after immunodepletion by total-body gamma irradiation, virus can colonize several other tissues, including lung tissue, in which it causes interstitial pneumonia (32) . (ii) Protective immunity can be conferred to immunodepleted recipients by transfer of specifically sensitized T lymphocytes that contain the CD8 (Lyt-2)-positive subset (32) . The antiviral efficacy of such cells can be enhanced by application of interleukin in vivo (31) . (iii) A high proportion of the sensitized CTL precursors contained in donor T lymphocyte populations are specific for cell membrane antigen(s) specified by IE genes. IE antigens are nonstructural viral antigens (29, 30) . (iv) A particular IE membrane antigen defined by the Ld-restricted CTL clone TEl (26) is expressed * Corresponding author.
in L(H-2k) fibroblasts cotransfected with the major histocompatibility complex (MHC) gene Ld and IE genes of MCMV (16, 17) . In infected cells, this antigen can be detected after enhanced, selective expression of IE genes and also during the late phase of MCMV replication (27) . (v) The major IE protein of MCMV, pp89, has a regulatory function in viral gene expression and is located in the nucleus of the infected cell (10, 11, 13, 15, 16) . Gene iel, encoding pp89, lacks nucleotide sequences that would predict membrane-spanning domains (12) .
Based on the finding that T lymphocytes of the CD8 subset mediate protective immunity (31, 32) , it has been a tacit assumption in our working hypothesis that IE-specific CTL perform a protective function. In this communication we provide the first evidence that CD8-positive T lymphocytes specific for IE [7] ) and anti-L3T4 (GK 1.5, IgG and complement (32) .
Cell surface phenotyping. For singlemetric analysis (FACS IV; Becton D tems, Sunnyvale, Calif.) of the CD phe were stained indirectly with MAbs an and GK with 1.5 (anti-CD4) and fli affinity-purified F(ab')2 fragments of I and goat anti-rat IgG (Jackson Immuno Pa.), respectively (26 (31, 32) have demonstrated that depletion of CD8-positive lymphocytes abrogates the ability of a sensitized lymph node cell population to control MCMV multiplication in tissues of immunodepleted cell transfer recipients. Cooperation with CD4-positive lymphocytes proved to be dispensable, while a requirement for donor-derived CD4-negative accessory cells has not been formally excluded. For relating antigen specificity to antiviral in vivo function of effector cells, we have now studied the properties of purified T-lymphocyte subsets after in vitro IL-2-mediated clonal expansion in the absence of antigen.
The composition of in vitro IL-2-propagated lymphocyte populations, derived from draining lymph nodes of infected donors, was determined by cytofluorometric analysis ( histograms) and CD8-CD4+ lymphocytes (right column). There was no indication of the existence of a non-CD4 non-CD8 population, demonstrating the depletion of B lymphocytes and accessory cell types during clonal expansion of T lymphocytes. Treatment with anti-CD8 MAb plus complement (second row in the array of fluorescence histograms) yielded a pure CD8-CD4+ population, while treatment with anti-CD4 MAb plus complement (third row) yielded a pure CD8+ CD4-population. The CD8 population contained cells with a low CD8 antigen density, a phenomenon that can be observed also with cloned long-term CTL lines (26) .
The in vivo antiviral activity of these purified, accessory cell-depleted T-lymphocyte subsets was probed by prophylactic adoptive transfer into immunodepleted, lethally infected recipient mice (32) , employing the lungs as a sensitive indicator site of MCMV replication (Fig. 2) Evidence for prevention of virus-mediated histopathology by transfer of CD8+ CD4-T lymphocytes was documented by in situ hybridization of lung tissue sections with cloned genomic fragments of MCMV (Fig. 3) . While after transfer of T lymphocytes depleted of the CD8 subset several clusters of infected cells could be detected with ease in each lung tissue section at day 14 postinfection (Fig. 3a) , MCMV DNA was only rarely detectable in lung tissue by screening a series of sections (Fig. 3b) after transfer of CD8+ CD4-T lymphocytes. The more dispersed appearance of the tissue in Fig. 3a reflects the widening of the alveolar septa during interstitial MCMV pneumonia, as has been demonstrated in a previous report (32) , whereas the tissue in Fig. 3b was phenotypically normal. This finding verified that the antiviral activity of CD8 effector cells was not accompanied by cell-mediated histopathology, but rather protected from virus-mediated tissue destruction.
In conclusion, the antiviral effector function in vivo can be assigned to the CD8-positive subset of specifically sensitized T lymphocytes. The CD4-positive subset was neither effective by itself nor essential for the function of the CD8 effector cells.
CD8-positive T lymphocytes specific for IE antigens control MCMV replication in vivo. In Fig. 4 , the in vitro cytolytic activity of a purified CD8-positive effector cell population is related to its in vivo antiviral function. In that experiment, the frequency of IL-2-receptive, i.e., sensitized, CTL precursors (IL-CTLp [28, 30] ) specific for antigens displayed by fibroblasts that selectively expressed IE genes of MCMV was estimated by limiting-dilution analysis (maximumlikelihood method [5] ) to be 1 of 7,680 (95% confidence range, 1 of 5,550 to 1 of 10,640; P = 0.78), which was in good J. VIROL. (Fig. 1, third row) accordance with previous estimates (30) , while the frequency of IL-CTLp specific for viral structural (S) antigens was <1 of 80,000.
The polyclonal lymphocyte population obtained after IL-2-mediated expansion was first depleted of the CD4 subset (Fig. 1, third row) and then incubated for antigen-specific depletion on fibroblast monolayers. CD8-positive lymphocytes recovered from noninfected monolayers (Fig. 4A ) lysed syngeneic IE target cells (IE-KD2SV, H-2d) with high efficacy. The recognition of IE antigens was MHC restricted, as MHC-mismatched IE target cells (IE-B6/WT-3, H-2b) were not lysed (not depicted). Also not lysed were syngeneic fibroblasts that displayed viral S antigens (S-KD2SV). Note that S-KD2SV was an appropriate target for lysis by CTL clones specific for S determinants of MCMV (26) . This result thus documented the absence of S-specific CTL in that effector cell population and reconfirmed that IE antigens and S antigens are separate entities recognized by different CTL (26, 29) . Accordingly, preincubation on monolayers carrying S antigens did not affect the anti-IE-directed lytic efficacy of the population (Fig. 4B ), whereas contact with monolayers that expressed IE genes profoundly did so (Fig. 4C) .
The in vivo antiviral efficacies of the three selected populations were compared by testing the ability of 20,000 cells to limit MCMV multiplication in the lungs of immunodepleted recipients (Fig. 4) . While preincubation on S monolayers had no significant effect (A and B, P = 0.1), depletion of IE-specific effector cells on IE antigen-expressing monolayers (panel C) resulted in a significant increase in virus titers (A and C, P = 0.005; B and C, P = 0.005; and A and B versus C, P < 0.001) to almost the control level (Fig. 2, column A) .
Altogether, these data established that CD8-positive lymphocytes specific for IE antigens of MCMV are able to limit virus multiplication in vivo.
Protection from a lethal course of disease and establishment of persistent infection. Two important questions remained to be answered: (i) was the numerically and histologically significant antiviral effect also significant quo ad vitam, and (ii), if so, did infection in surviving cell transfer recipients then attain a latent or a persistent state (9)?
For the correct evaluation of the results shown in Fig. 5 , it is important to recollect some basic facts of the experimental model detailed in a previous report (32) . Immunodepletion as a consequence of total-body gamma irradiation with a radiation dose of 6 Gy (equal to a lethal dose referred to as LD50/30 in reference 37) causes, on average, 50% of adult (8-to 10-week-old) female BALB/c mice to die within an observation period of 30 days. Without exception, immunodepleted mice die of acute CMV disease after infection, while immunocompetent mice all survive.
CD8-positive lymphocytes selected for the recognition of viral nonstructural antigens (Fig. 4B) were transfused into lethally infected recipients (Fig. 5) Fig. 4B ). In one of the recipients (in group II) that had survived until the end of the 30-day monitoring period, necrosis at the plantar site of infection was not cured. This individual died at day 42 postinfection (not depicted).
VOL. 61, 1987 3106 REDDEHASE ET AL. postinfection (Fig. 5, shaded area) . The terminal stage of CMV disease was signified by a severe wasting syndrome, extensive hemorrhages spreading from the plantar site of infection, and necrosis in several tissues, including the lungs, the liver, and the adrenal glands. Transfer of only 20,000 specific lymphocytes significantly retarded death from CMV disease, and 3 of 20 mice survived (Fig. 5, graph  I ). Note that hemorrhages in the footpad developed in all mice until day 10 postinfection and were completely healed in the survivors by day 30 A month later, at day 60 postinfection, titers of MCMV in tissue were determined for the salivary glands, the spleen, and the lungs of survivors from all three lymphocyte transfer groups (Fig. 6 ). With two exceptions (group I, recipient 3, and group II, recipient 6), the presence of infectious virus in the salivary glands indicated that viral latency was not established. With one exception (group III, recipient 4), viral replication had ceased in the spleen, while infectious virus was detected in the lungs in two of three (group I), three of six (group II), and two of seven (group III) recipients. The individual scoring revealed only a few mismatches in the rank of virus titers observed in salivary glands and lungs (group II, recipients 2, 3, and 4). In these recipients, MCMV was present in the salivary glands but not in the lungs. Consistent with the known fact that salivary glands represent the most permissive site for MCMV replication (20, 32) , the reverse case was not observed, and the virus titers in the salivary glands were significantly higher than those in the lungs of the same individuals.
Seroconversion was observed in all individuals, indicating autoreconstitution of humoral immunity, but there was no correlation between MCMV-specific serum antibody titers and virus titers in any of the organs tested (data not shown).
In conclusion, CD8-positive T for a model because interstitial pneumonia caused by opportunistic primary or recurrent human CMV infection is a clinical problem in leukemia patients after irradiation (21, 25) . Our present data concur with our previous studies (31, 32) in the conclusion that control of virus multiplication in the lungs is a function of the CD8 subset of specifically sensitized T lymphocytes and prove in addition that purified CD8+ CD4-effector cells do not require the help provided by CD4 lymphocytes to protect against tissue destruction and mediate survival.
The mechanism by which CD8 lymphocytes exert their antiviral effect in vivo is still open to question, and a solution of this problem is beyond the scope of this contribution. Two aspects, however, deserve consideration. First, remarkably few cells were required for conferring protection (Fig. 3 and  5) , and second, only specifically sensitized lymphocytes inhibited virus multiplication (Fig. 2) . A seemingly low probability for antiviral effector cells to encounter their targets in vivo has been adduced as an argument in favor of a lymphokine effect (18 persistent virus replication was detected in the salivary glands of most and in the lungs of some survivors (Fig. 6 ), although these individuals appeared healthy, had cured the hemorrhages at the plantar site of infection, and had reconstituted their immune system, as manifested by a humoral immune response to MCMV. There was no indication of a role for antiviral antibody in the control of MCMV replication, as antibody titers in serum did not correlate with virus titers in any of the organs tested. Persistent infection and tissue distribution of MCMV during reconstitution of the immune system after irradiation resemble the infection in newborn mice, while in adult immunocompetent mice the lungs are not affected and MCMV replication is confined to the salivary glands, where it ceases after about 6 weeks (32; G. M. Keil et al., unpublished observations). The occurrence of substantial virus replication in the lungs of phenotypically healthy survivors (Fig. 6) indicates that infection at that site is not inevitably lethal. Adrenal cortical dysfunction (31, 36) or failure in hematopoiesis (W. Mutter, M. J. Reddehase, F. Busch, H.-J. Buhring, and U. H. Koszinowski , manuscript in preparation) might turn out to be a more decisive factor.
The most important aspect in our results concerns the antigen specificity of protective effector cells. An in vivo antiviral function could be attributed to CD8+ CD4-T lymphocytes that displayed an in vitro CTL activity against target cells selectively expressing nonstructural IE gene products, but not against target cells presenting viral structural antigens (Fig. 4A) . Recognition by CTL of nonstructural antigens encoded during the early and late phases of MCMV replication could not be assessed, because selective expression of early-and late-gene products in the absence of IE gene products is technically not feasible as yet. Note that pp89, the major IE protein (13) , once synthesized during the IE phase, remains detectable in infected cells throughout the viral replication cycle and is synthesized again during the late phase (27) . For this reason, antigen-specific depletion of lymphocytes and testing of the residual population was the more conclusive approach to the identification of antiviral effector cells. Significant reduction in both in vitro IEspecific lytic activity and in vivo antiviral function by preincubating sensitized CD8+ CD4-T lymphocytes on monolayers that selectively expressed IE antigens positively identified IE-specific T lymphocytes of the CD8 subset as in vivo-operating antiviral effector cells.
It is still open to question why, in the immunocompetent host, CTL specific for structural antigens of MCMV occur less frequently than IE-specific CTL (30) and are often not detectable at all. It has been discussed previously (30) that in the immunocompetent host, infection is not productive in tissues, except for the salivary glands, and hence effective priming of CTL precursors specific for virion structural antigens may not occur. Based on the present findings it could be speculated that, by eradicating infected cells at an early stage, the high in vivo antiviral efficacy of IE-specific effector cells is directly responsible for the failure to generate a structural antigen-specific CTL response.
